Targeting KRAS in Pancreatic Cancer

Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies th...

Descripción completa

Detalles Bibliográficos
Autores principales: Cowzer, Darren, Zameer, Mohammed, Conroy, Michael, Kolch, Walter, Duffy, Austin G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692903/
https://www.ncbi.nlm.nih.gov/pubmed/36579598
http://dx.doi.org/10.3390/jpm12111870
_version_ 1784837389942784000
author Cowzer, Darren
Zameer, Mohammed
Conroy, Michael
Kolch, Walter
Duffy, Austin G.
author_facet Cowzer, Darren
Zameer, Mohammed
Conroy, Michael
Kolch, Walter
Duffy, Austin G.
author_sort Cowzer, Darren
collection PubMed
description Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines.
format Online
Article
Text
id pubmed-9692903
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96929032022-11-26 Targeting KRAS in Pancreatic Cancer Cowzer, Darren Zameer, Mohammed Conroy, Michael Kolch, Walter Duffy, Austin G. J Pers Med Review Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines. MDPI 2022-11-08 /pmc/articles/PMC9692903/ /pubmed/36579598 http://dx.doi.org/10.3390/jpm12111870 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cowzer, Darren
Zameer, Mohammed
Conroy, Michael
Kolch, Walter
Duffy, Austin G.
Targeting KRAS in Pancreatic Cancer
title Targeting KRAS in Pancreatic Cancer
title_full Targeting KRAS in Pancreatic Cancer
title_fullStr Targeting KRAS in Pancreatic Cancer
title_full_unstemmed Targeting KRAS in Pancreatic Cancer
title_short Targeting KRAS in Pancreatic Cancer
title_sort targeting kras in pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692903/
https://www.ncbi.nlm.nih.gov/pubmed/36579598
http://dx.doi.org/10.3390/jpm12111870
work_keys_str_mv AT cowzerdarren targetingkrasinpancreaticcancer
AT zameermohammed targetingkrasinpancreaticcancer
AT conroymichael targetingkrasinpancreaticcancer
AT kolchwalter targetingkrasinpancreaticcancer
AT duffyausting targetingkrasinpancreaticcancer

Ejemplares similares